Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00247
|
|||||
| Drug Name |
Vasopressin
|
|||||
| Synonyms |
ADH (hormone); American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Beta-Hypophamine; Inyectable de vasopresina; Inyectable de vasopresina [INN-Spanish]; Leiormone; Monarch Brand of Vasopressin; Parke-Davis Brand of Vasopressin (USP); Pitressin; Pitressin (TN); Pituitrin; Solute injectable de vasopressine; Solute injectable de vasopressine [INN-French]; Tonephin; Vasopressin (JP15/USP); Vasopressin (USP); Vasopressin Monarch Brand; Vasopressin injection; Vasopressina; Vasopressina [DCIT]; Vasopressine; Vasopressini injectio; Vasopressini injectio [INN-Latin]; Vasopressins; Vasopressinum
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Diabetes [ICD11: 5A10-5A14] | Approved | [1] | |||
| Enuresis [ICD11: 6C00] | Approved | [1] | ||||
| Polyuria [ICD11: MF55] | Approved | [1] | ||||
| Therapeutic Class |
Vasoconstrictor Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C46H65N15O12S2
|
|||||
| Canonical SMILES |
C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N
|
|||||
| InChI |
InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
|
|||||
| InChIKey |
KBZOIRJILGZLEJ-LGYYRGKSSA-N
|
|||||
| CAS Number |
CAS 11000-17-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 1084.2 | Topological Polar Surface Area | 515 | ||
| Heavy Atom Count | 75 | Rotatable Bond Count | 19 | |||
| Hydrogen Bond Donor Count | 14 | Hydrogen Bond Acceptor Count | 16 | |||
| XLogP |
-4.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
104083701
, 109827448
, 134974187
, 135651625
, 140377228
, 144206588
, 15411997
, 160650127
, 162254868
, 163312391
, 163346232
, 17397139
, 179694497
, 223435346
, 226427648
, 246709883
, 249582977
, 29218064
, 43765812
, 50111753
, 53789769
, 57408192
, 74876209
, 7980875
, 841489
, 85856460
, 99313696
|
|||||
| ChEBI ID |
CHEBI:34543
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| References | ||||||
| 1 | Vasopressin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.